Ascletis’ ASC39 is an experimental pill designed to activate the amylin receptor using a small molecule. This signal is part of a hormone system that helps control appetite, slows stomach emptying, and smooths out post-meal blood-sugar spikes. While being developed with obesity treatment in mind, the amylin pathway is tightly linked to diabetes care.
Amylin is normally released alongside insulin from the pancreas, but in diabetes cases, amylin signalling can be reduced or out of balance. That matters because insulin alone doesn’t fully replicate the body’s natural “meal-time” control system. Drugs that mimic or stimulate amylin effects can support better after-meal glucose control, reduce appetite-driven overeating, and promote weight loss. These are outcomes that can translate into better diabetes management.
Go deeper with GlobalData
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.
The early head-to-head performance of ASC39 against eloralintide, exhibited at the American Diabetes Association (ADA) Annual Meeting, is what makes it notable. Eloralintide is a once-weekly injectable amylin analog peptide that has already shown promising results in trials. A rodent study found that EC50s for human amylin 1 receptor (hAMY1R) were 21.4 pM for ASC39 and 21.2 pM for eloralintide. Comparison of human calcitonin receptor (hCTR) saw 846.1 pM for ASC39 and 1350.8 pM for eloralintide. The data shows selectivity of hAMY1R over hCRT to be 40-fold for ASC39 and 64-fold for eloralintide.
ASC39 still has a long road of trials ahead to establish whether it improves glucose outcomes for metabolic diseases. Human trials will need to show the impact on A1C and post-meal glucose, track side effects, and test how it interacts with other therapies like insulin and GLP-1 drugs. A convenient oral option would be a significant advantage over other amylin receptor agonists.
ASC39 is a development candidate with an exciting profile. As an oral, selective amylin receptor agonist with strong preclinical potency and weight-loss signals, it represents a potentially practical new way to target a pathway that sits at the crossroads of appetite, weight, and blood-sugar control.
